CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia  by Iwasaki, Masayuki et al.
ArticleCD93 Marks a Non-Quiescent Human Leukemia
Stem Cell Population and Is Required for
Development of MLL-Rearranged Acute Myeloid
LeukemiaGraphical AbstractHighlightsd Cell surface lectin CD93 is a functional marker of LSCs in
MLL-rearranged AML
d CD93+ LSCs are cycling, non-quiescent leukemia-initiating
cells
d LSC expression of CD93 is essential for MLL-mediated
leukemogenesis
d CD93 regulates LSC self-renewal by silencing CDKN2B in
MLL leukemiaIwasaki et al., 2015, Cell Stem Cell 17, 412–421
October 1, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.stem.2015.08.008Authors
Masayuki Iwasaki, Michaela Liedtke,
Andrew J. Gentles, Michael L. Cleary
Correspondence
mcleary@stanford.edu
In Brief
Iwasaki et al. demonstrate that leukemia
stem cells (LSCs) in a distinctive genetic
subtype of leukemia are non-quiescent.
Although human LSCs are typically
enriched in the highly quiescent
CD34+CD38 phenotypic compartment,
co-expression of the lectin CD93 further
demarcates LSCs as a discrete
subpopulation of actively cycling, non-
quiescent AML cells.Accession NumbersGSE64773
GSE64776
Cell Stem Cell
ArticleCD93 Marks a Non-Quiescent Human Leukemia Stem
Cell Population and Is Required for Development
of MLL-Rearranged Acute Myeloid Leukemia
Masayuki Iwasaki,1 Michaela Liedtke,2 Andrew J. Gentles,3 and Michael L. Cleary1,*
1Department of Pathology
2Department of Medicine
3Department of Radiology
Stanford University School of Medicine, Stanford, CA 94305, USA
*Correspondence: mcleary@stanford.edu
http://dx.doi.org/10.1016/j.stem.2015.08.008SUMMARY
Leukemia stem cells (LSCs) are thought to share
several properties with hematopoietic stem cells
(HSCs), including cell-cycle quiescence and a capac-
ity for self-renewal. These features are hypothesized
to underlie leukemic initiation, progression, and
relapse, and they also complicate efforts to eradicate
leukemia through therapeutic targeting of LSCs
without adverse effects on HSCs. Here, we show
that acute myeloid leukemias (AMLs) with genomic
rearrangementsof theMLLgenecontain anon-quies-
cent LSC population. Although human CD34+CD38
LSCs are generally highly quiescent, the C-type lectin
CD93 is expressed on a subset of actively cycling,
non-quiescent AML cells enriched for LSC activity.
CD93 expression is functionally required for engraft-
ment of primary human AML LSCs and leukemogen-
esis, and it regulates LSC self-renewal predominantly
by silencing CDKN2B, a major tumor suppressor
in AML. Thus, CD93 expression identifies a predomi-
nantly cycling, non-quiescent leukemia-initiating
cell population in MLL-rearranged AML, providing
opportunities for selective targeting and eradication
of LSCs.
INTRODUCTION
Acutemyeloid leukemia (AML) is organizedas acellular hierarchy,
relying on self-renewing leukemia stemcells (LSCs) at the apex to
generate non-self-renewing blasts and differentiated progeny
cells. LSCs typically comprise a small minority of cells within the
hierarchy, but their relative abundance may be clinically signifi-
cant since recent studies suggest that detection of an LSC or
‘‘stemness’’ gene expression signature in AML is associated
with a poor prognosis (Gentles et al., 2010; Eppert et al., 2011).
From a clinical perspective, it has been demonstrated that LSCs
are resistant to standard chemotherapy and are retained and
give rise to relapse (Jordan et al., 2006; Ishikawa et al., 2007;
Konopleva and Jordan, 2011). Thus, LSCs are the ultimate thera-412 Cell Stem Cell 17, 412–421, October 1, 2015 ª2015 Elsevier Inc.peutic target to eradicate AML without killing normal hematopoi-
etic stem cells (HSCs), but this strategy depends on identifying
and exploiting biomarkers or pathways that are differentially ex-
pressed by LSCs and may functionally sustain leukemogenesis.
Both HSCs and LSCs share the properties of self-renewal,
quiescence, and expression of a CD34+CD38 immunopheno-
type (Bhatia et al., 1997; Bonnet and Dick, 1997; Lapidot et al.,
1994). However, in some cases LSCs may be phenotypically
distinguished from HSCs by preferential expression of cell
surface proteins such as CD123, CD44, CLL-1, CD96, CD47,
CD25, CD32, or TIM-3 (Jordan et al., 2000; Jin et al., 2006; van
Rhenen et al., 2007; Hosen et al., 2007; Jaiswal et al., 2009;
Majeti et al., 2009; Saito et al., 2010; Kikushige et al., 2010;
Jan et al., 2011). Expression of TIM-3 is particularly discrimina-
tory, capable of distinguishing highly mutated LSCs from less
mutated pre-leukemic HSCs (Jan et al., 2011), suggesting a po-
tential function underlying the progressive evolution of mutated
HSCs to bona fide LSCs. Other differentially expressed antigens
function in immune recognition or its evasion, thus providing a
mechanistic rationale as candidate targets for immunotherapies
(Jin et al., 2006, 2009; Majeti et al., 2009; Kikushige et al., 2010).
However, not all AML subtypes consistently express the fore-
going antigens, raising the issue of whether alternative surface
markers may be selectively expressed by LSCs in specific
genetic subtypes of AML. Furthermore, surface markers that
distinguish LSCs versus HSCs have not generally been mecha-
nistically linked with essential LSC functions, particularly those
that underlie self-renewal or cell-cycle regulation. Although
LSCs are enriched in a highly quiescent phenotypic compart-
ment of the AML hierarchy, theymust nevertheless actively cycle
to self-renew, sustain disease, and facilitate clinical relapse. It is
likely that LSC phenotypes and cycling characteristics vary with
different genetic subtypes of AML, which are remarkably diverse
in terms of developmental and pathological characteristics.
Here we report that the cell surface lectin CD93 is a functional
marker of LSCs in a specific genetic subtype of AML with
genomic rearrangements of the MLL (Mixed Lineage Leukemia)
gene. CD93 selectively marks and essentially maintains LSCs
and identifies them as predominantly cycling, non-quiescent
leukemia-initiating cells. CD93 promotes LSC proliferation in
part through silencing of CDKN2B, a major cell-cycle inhibitor
and tumor suppressor whose expression is silenced in amajority
of AMLs with poor prognosis.
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Figure 1. CD93 Expression on Human CD34+CD38– AML and Cord Blood Cells
(A and B) Flow cytometry plots show CD93 expression on CD34+CD38 AML cells of MLLr patient #2 (A) and non-MLLr patient #19 (B).
(C) Flow cytometry plot shows CD93 expression on Lin CD34+CD38 cord blood cells.
(D) Dot plot summarizes the relative CD93 expression on CD34+CD38 cells from the indicated sources.
See also Figures S1 and S2 and Table S1.RESULTS
Identification of Surface Markers Differentially
Expressed by LSCs
A leukemia cell fraction highly enriched for LSCs was generated
in a mouse model of AML induced by co-expression of MLL
target genes HoxA9 and Meis1. Limiting dilution transplantation
analyses performed on various prospectively isolated leukemia
cell subpopulations revealed that cells capable of transplanting
AML into syngeneic recipient mice (the operational definition ofCD34+
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CeLSCs) were highly enriched in the leukemia cell fraction, display-
ing an immunophenotype (Lin Sca1 c-Kit+ CD16/32+CD34+)
comparable to that of normal granulocyte macrophage progen-
itors (GMPs) (Figures S1A and S1B), referred to as L-GMPs.
Gene expression profiling identified 2,291 genes that were
differentially expressed (at least 1.5-fold) in L-GMPs versus
GMPs (1,027 upregulated versus 1,264 downregulated). Ten of
the significantly upregulated genes encoded candidate cell sur-
face molecules (Figure S1C). These included CD93, a C-type
lectin implicated in cellular adhesion, whose surface expressionCD38-
CD93-
CD34+CD38-
Figure 2. CD34+CD38–CD93+ Human AML
Cells Are Highly Enriched in LSC Activity
(A) Bar graph shows CFC frequencies for
FACS-sortedCD34+CD38CD93+ orCD34+CD38
CD93 cells from primary MLLr AMLs (n = 5) plated
in methylcellulose for 12 days. Data are the mean
number of colonies (±SEM) per 5,000 plated AML
cells. *p = 0.0006.
(B) Representative colony morphologies are
shown for the experiment in (A).
(C) LSC frequencies were determined by limiting-
dilution transplantation of FACS-sorted CD34+
CD38CD93+ or CD34+CD38CD93 AML sub-
populations.
See also Figures S3 and S4 and Tables S2 and S3.
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Figure 3. The Gene Expression Profile of the CD93+ LSC Subpopula-
tion Strongly Correlates with Cell-Cycle-Related Genes
(A) GO analysis of genes upregulated in the LSC-enriched CD34+
CD38CD93+ AML subpopulation based on their biological process annota-
tions.
(B) GSEA plots show upregulation of cell-cycle-process-related genes in the
LSC-enriched CD34+CD38CD93+ AML subpopulation.appeared strongly correlated withMeis1 levels in co-expression
experiments with either HoxA9 or MLL oncogenes (Figure S2).
Thus, we focused our subsequent studies onCD93 as a potential
cell surface antigen to functionally delineate LSCs in Hox-asso-
ciated leukemia containing MLL rearrangements.
CD93 Is a Functional Marker of LSCs in
MLL-Rearranged AML
In most human AMLs, LSCs are enriched in the CD34+CD38
cell fraction (Bonnet and Dick, 1997), which also contains normal
HSCs and multipotent progenitors. Therefore, we evaluated the
CD93 expression profile on CD34+CD38 cells comprising
various human AMLs (Table S1) and normal cord blood by
flow cytometry (representative results are shown in Figures
1A–1C). CD93 was expressed on a significant, albeit variable,414 Cell Stem Cell 17, 412–421, October 1, 2015 ª2015 Elsevier Inc.percentage of cells in the CD34+CD38 fraction of MLL-rear-
ranged (MLLr) leukemias (Figure 1D). In contrast, the compara-
ble subpopulations within non-MLLr leukemias or cord blood
cells (Lin CD34+CD38 fraction) generally lacked significant
expression of CD93 (Figure 1D) although the bulk AML popula-
tion in some non-MLLr leukemias contained cells with high
CD93 expression. Thus, CD93 is selectively expressed on a sub-
set of cells within the stem/progenitor cell-enriched subpopula-
tion of MLLr AML.
Since CD93 expression phenotypically subdivides the
CD34+CD38 population of human MLL leukemia, we assessed
whether its presence may correlate with functional properties of
LSCs. Colony-forming assays performed on prospectively iso-
lated MLLr AML cells revealed that clonogenic activity was at
least 10-fold higher in the CD93+ fraction compared with the
CD93 fraction of CD34+CD38 cells (Figure 2A and Fig-
ure S3A). The compact morphology of many colonies generated
by CD34+CD38CD93+ cells versus uniformly diffuse colonies
induced by CD34+CD38CD93 cells (Figure 2B) suggested
that the former may be composed of a high proportion of prolif-
erating cells. CD93+ also enriched for CFC (colony-forming cell)
activity within the CD34+CD38+ fraction albeit to a lesser extent
(Figure S3A). Very high CD93 levels (CD93++) were present on
terminally differentiated non-clonogenic myeloid cells in the un-
fractionated AML population (Figure S3B). To determine
whether LSCs were more enriched in the CD93+ cell fraction,
limiting dilution xenotransplantation experiments were per-
formed in NSG recipient mice. Consistent with the CFC assays,
prospectively isolated CD34+CD38CD93+ cells induced leuke-
mia much more efficiently than CD34+CD38CD93 cells (Table
S2). Estimation of LSC frequencies based on Poisson statistical
analysis indicated that LSCs were at least 100-fold more preva-
lent in the CD34+CD38CD93+ subpopulation (Figure 2C).
CD93 also enriched for LSCs outside of the CD34+CD38
subpopulation (CD34+CD38+) of AML (Table S3). The xenograft
leukemia cells were of human origin (hCD45+), displayed
myeloid immunophenotypes, and consisted of CD34/CD38/
CD93 subpopulations similar to the primary human AMLs
(Figure S4). Leukemias serially engrafted secondary transplant
recipients (data not shown), indicating that the originally injected
CD34+CD38CD93+ cells were composed of self-renewing
LSCs. Taken together, these results indicate that CD93 expres-
sion further enriches for a subpopulation of MLLr AML cells with
functional properties of LSCs.
CD93+ LSCs in MLL-Rearranged AML Are
Non-Quiescent
Global gene expression profiling analysis was performed to
identify the genes and pathways that correlated with CD93
expression in MLLr LSCs. Comparison of gene expression
profiles of the LSC-enriched (CD34+CD38CD93+) versus
LSC-depleted (CD34+CD38CD93) populations from within
individual leukemias revealed 374 differentially expressed
(at least 1.3-fold) probe sets (258 upregulated versus 116
downregulated). Classification based on gene ontology (GO)
showed that the ten most significant annotation groups for
upregulated genes in CD34+CD38CD93+ cells consisted
of cell-cycle genes (Figure 3A). Furthermore, gene set
enrichment analysis (GSEA) revealed significant enrichment
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Figure 4. MLL LSCs Are Enriched for G1
Cycling Cells, Not G0 Quiescent Cells
(A and B) Representative flow cytometry plots
show Hoechst/Pyronin Y staining profiles for the
indicated AML cell subpopulations.
(C) Bar graph shows the cell-cycle profiles for
the indicated MLLr AML cell subpopulations as
determined by flow cytometry. Data are mean
values from three human MLLr AMLs with statisti-
cally significant differences in G0 (p = 0.0133) and
G1 (p = 0.0111) subpopulations.
(D) Bar graph denotes the relative colony numbers
generated by G0 versus G1 phase cells isolated by
FACS from humanMLLr CD34+CD38CD93+ cells.
Error bars indicate SDs of five independent ex-
periments. *p = 0.0184.
(E) Bar graph denotes the relative colony numbers
generated by G0 versus G1 phase cells isolated by
FACS from CD34+CD38 cord blood cells. Error
bars indicate SDs of three independent experi-
ments. *p = 0.0141.
(F) Survival curves are shown for cohorts of mice
transplanted with G0 or G1 phase cells (1,000 cells)
isolated from the CD34+CD38CD93+ subpopula-
tion of MLLr AML cells by FACS with Hoechst/Py-
ronin Y staining (n = 9 per cohort representing three
human MLLr AML injected into three mice each).
Acute leukemia was confirmed by flow cytometry
(engraftment) and necropsy.
See also Figure S5 and Tables S4–S6.for cell-cycle-related gene sets, including Rb- and E2F-
regulated genes (Figure 3B). Thus, the CD93+ LSC-enriched
subpopulation of MLLr AML differentially expresses activated
cell-cycle genes.
The gene expression profiling results prompted studies to
determine whether human MLLr LSCs are quiescent as sug-
gested for most cancer stem cells or cycling, non-quiescent
cells. Cell-cycle status was quantified by flow cytometry based
on Hoechst and Pyronin Y staining in human MLLr AML cells
comprising phenotypic subpopulations that differentially ex-
press CD34 and CD38. Consistent with previous studies, the
CD34+CD38 subpopulation, which has been reported
as LSC-enriched in AML, was the most quiescent of the
phenotypic subpopulations (Figure 4A). However, further sub-
division based on CD93 expression showed that despite the
apparent quiescence of the overall CD34+CD38 fraction,
cycling cells were highly enriched in the CD34+CD38CD93+
subpopulation, consistent with the microarray results (Figures
4B and 4C). Prospective subfractionation of CD34+
CD38CD93+ cells based on their cell-cycle status showed
that G1 fraction (cycling) cells formed about 30-fold more col-
onies than G0 quiescent cells (Figure 4D). This contrasted with
normal cord blood cells, which contained more CFCs in the G0
quiescent fraction compared to the G1 cycling fraction of LinCell Stem Cell 17, 412–42CD34+CD38 cells (Figure 4E). Xeno-
transplantation of prospectively isolated
G0 versus G1 phase CD34+CD38
CD93+ cells from MLLr AML showed
that G1 cells induced AML with higher
incidence and shorter latency than G0quiescent cells (Figure 4F and Table S4). In contrast, engrafting
LSCs of non-MLLr AMLs were only present in the G0 subfrac-
tion of CD34+CD38 cells (Table S5). Flow cytometry analysis
of the xenograft AMLs demonstrated similar CD34/CD38 pro-
files and composition of cycling CD93+ G1 cells (Figure S5)
to those in primary patient AMLs (Figures 4A and 4B). The
G1 phase CD34+CD38CD93+ cells from xenograft MLLr
AML serially engrafted secondary recipients, indicating that
the G1 cells have strong stem cell function and self-renew to
produce themselves whereas G0 cells do not (Table S6). Taken
together, these studies indicate that LSCs in human MLLr AML
are highly enriched for actively cycling cells, in contrast to the
quiescence of non-MLLr LSCs and cancer stem cells in
general.
CD93 Is Essential for MLL Leukemogenesis
To assess whether CD93 may bemore than a passive marker for
cycling LSCs and thus required for maintenance of MLL leuke-
mogenesis, its expression was knocked down in human MLLr
leukemia cells using shRNA techniques. Efficient (>70%–80%)
knockdown of CD93 expression dramatically reduced the clono-
genic growth of human MLLr leukemia cells (Figures 5A and 5B)
and promoted terminal leukemia cell differentiation compared
with knockdown control (shLuc transduced) cells (Figure 5C)1, October 1, 2015 ª2015 Elsevier Inc. 415
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Figure 5. CD93 Is Required for MLL Leukemogenesis
(A) Bar graph denotes transcript levels of CD93 as assayed by qRT-PCR
of primary human MLLr leukemia cells transduced with lentiviral vectors en-
coding the indicated shRNAs.
(B) Bar graph shows the relative CFC activity of human MLLr AML cells and
cord blood cells transduced with the indicated shRNAs. Error bars indicate
SDs of five (human MLLr AML) and three (cord blood) independent experi-
ments. *p < 0.0001.
(C) May-Grunwald-Giemsa-stained cytopreps show the morphologic features
of human MLLr AML cells expressing the indicated shRNAs after methylcel-
lulose culture (day 12).
(D) Graphs show the relative numbers of human leukemia cells transduced
with the indicated shRNAs present in the BM of NSG recipient mice after
seven (MLLr) or nine (non MLLr) weeks post-transplantation, respectively.
Data shown are representative of two cases each of MLLr and non-MLLr
AMLs. Error bars indicate SDs of three independent mice.or normal cord blood cells, which were unaffected (Figure 5B).
Xenotransplantation experiments were performed to assess
the potential in vivo dependence of primary human AML cells
on CD93. Following lentiviral transduction of shRNAs and
transplantation of unselected cells into NSG recipient mice,
engraftment and disease progression were monitored by flow
cytometry to quantify the relative proportions of human AML
cells (hCD45+) that were knocked down for CD93 (mCherry+) in
bone marrow (BM) at 7–9 weeks post-transplant. CD93 knock-
down markedly inhibited in vivo leukemia cell growth of MLLr
AML with minimal effects on non-MLLr AML (Figure 5D). These
results demonstrate that the cell surface lectin CD93, which
marks cycling LSCs, contributes an essential function that sus-
tains human MLL leukemogenesis.416 Cell Stem Cell 17, 412–421, October 1, 2015 ª2015 Elsevier Inc.CD93 Is Required for Initiation and Establishment of
Hox-Associated Leukemia
The role of CD93 in MLL leukemogenesis was further investi-
gated using a murine model that recapitulates the features of
human MLLr leukemia. Similar to human MLLr AML, LSCs
were enriched in the CD93+ subpopulation (Figure S6) and
CD93 knockdown substantially decreased clonogenicity and
growth of MLL leukemia cells in vitro (Figures 6A–6C). The
requirement for CD93 appeared to be selective for myeloid cells
transformed by oncoproteins that dysregulate the Hox pathway
including MLL and NUP98-HOXA9 (Figure 6D). CD93 knock-
down colonies were smaller, more diffuse, and composed of
morphologically more differentiated cells, supporting a role for
CD93 in promoting maturation arrest and self-renewal (Fig-
ure 6E). CD93 knockdown AML cells were unable to induce
leukemia in secondary transplant assays (Figure 6F) consistent
with their more differentiated phenotype (lower c-Kit and higher
Mac1 and Gr-1 expression) (Figure 6G). Together, these data
demonstrate that CD93 is an essential regulator that selectively
maintains MLL LSC oncogenic potential through enhanced
self-renewal and maturation arrest.
CD93 Regulates LSC Self-Renewal by Suppression of
Cdkn2b in MLL Leukemia
To assess the mechanistic role of CD93 in regulating LSC
self-renewal, AML cells were analyzed by flow cytometry for
cell-cycle status following CD93 knockdown. Both human
and murine knockdown AML cells were more quiescent
(increased G0 cells) compared with control cells, suggesting
that CD93 plays a crucial role in modulating cell cycle in MLL
leukemia cells (Figures 7A–7C). Notably, qRT-PCR analysis of
candidate cell-cycle regulators demonstrated substantial upre-
gulation of the cell-cycle inhibitor Cdkn2b (p15Ink4b) in CD93
knockdown versus control AML cells (Figures 7D and 7E).
These results suggested a potential model wherein CD93
may functionally suppress Cdkn2b expression and prevent
cell-cycle quiescence to promote LSC self-renewal. To test
this model, we attempted to bypass the cell-cycle suppression
caused by CD93 knockdown using cells from Cdkn2b/ mice
(Figure 7F). MLL-transformed cells deficient for Cdkn2b were
significantly more resistant to the loss of clonogenicity induced
by CD93 knockdown (Figure 7G) and were able to circumvent
loss of maturation arrest as evidenced by colony morphology
and cellular cytology (Figure 7H). Furthermore, Cdkn2b defi-
ciency significantly attenuated the shift from G1 to G0 induced
by CD93 knockdown (Figure 7I compared to Figure 7C) and
rescued the leukemogenic potential of CD93 knockdown AML
cells (Figure 7J compared to Figure 6F). Consistent with these
results, overexpression of Cdkn2b in MLL leukemia cells
induced morphologic differentiation and markedly suppressed
oncogenic activity in colony-forming assays and transplanta-
tion assays (Figure 7K and Figure S7). Thus, CD93 sustains
LSC oncogenic potential of MLLr AML primarily through sup-
pression of Cdkn2b.
DISCUSSION
We identified the cell-surface lectinCD93 as an LSC-specific sur-
face molecule in MLL-rearranged AML. The various genetic
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Figure 6. CD93 Is Required for Murine Hox-
Associated Leukemia Development
(A) Bar graph shows relative CD93 transcript levels
determined by qRT-PCR for primary murine MLL-
AF9 leukemia cells transduced with the indicated
shRNAs.
(B) Bar graph shows the relative CFC activity of
murine MLL-AF9 AML cells transduced with the
indicated shRNAs.
(C) Graph shows cell numbers (expressed as fold-
change relative to day 0) for culture of murine MLL-
AF9 leukemia cells expressing control or CD93
(construct c) shRNAs. Error bars indicate SDs of
three independent experiments.
(D) Bar graph denotes the relative CFC activities of
murine AML cells induced by the oncogenes listed
below and expressing the indicated shRNAs. Error
bars indicate SDs of at least three independent
experiments. *p < 0.0001.
(E) Representative images are shown for typical
colonies and cellular morphology (May Grunwald
Giemsa stain) for murine MLL-AF9 AML cells ex-
pressing CD93 or control shRNAs after methyl-
cellulose culture (day 5).
(F) Survival curves are shown for mice transplanted
with murine MLL-AF9 AML cells (5,000 cells)
transduced with shRNAs targeting CD93 (n = 5) or
luciferase (n = 5).
(G) Flow cytometry profiles show representative
expression levels for the indicated surface markers
on murine MLL-AF9 AML cells expressing CD93
or control shRNAs after methylcellulose culture
(day 5). Red boxes highlight significant changes in
myeloid antigens.
See also Figure S6.subtypes of AML display remarkable diversity in their develop-
mental characteristics and pathological phenotypes, and a sub-
type-specific LSC marker has not been previously described.
Furthermore, the LSCsmarked byCD93 expression are predom-
inantly cycling and comprise a minor component of an otherwise
quiescent CD34+CD38 compartment of human AML. The
cycling character of CD93+ LSCs was evident in their gene
expression profiles and confirmed by xenotransplantation of
FACS-sorted cycling versus quiescent cells from the same pa-
tient AML samples. The fact that LSCs in human MLLr AML are
actively cycling contrasts with previous studies demonstrating
that cancer stem cells are predominantly quiescent (Jordan
et al., 2006) and our own analyses of non-MLLr AMLs (Table
S5), but it is consistent with previous studies in a mouse model
of MLL leukemia (Somervaille et al., 2009). Nevertheless, we
cannot exclude the possibility of a rare quiescent LSC population
in MLLr AML. Importantly, CD93 is more than a passive marker
co-expressed on LSCs, but rather is required for LSC function,
constituting an essential role for a lectin in LSC biology. By
contrast, the C-type lectin-like molecule CLL-1, which is ex-
pressed on the whole blast compartment of many AMLs, has
not been shown to be essential or selectively enrich LSCs (vanCell Stem Cell 17, 412–42Rhenen et al., 2007). We hypothesize
that when CD93 expression falls below a
certain threshold CDKN2B is activated,cells exit the cycle, and they initiate differentiation out of the
LSC compartment.
The association of CD93 with LSCs in MLLr AML, but not other
genetic subtypes, likely reflects the fact that highCD93expression
correlateswith elevated levels ofMEIS1, an essential downstream
effector in the transcriptional cascade subordinate to MLL onco-
proteins, although CD93 does not appear to be a direct target
gene of MEIS1. Consistent with our results, CD93 was reported
as one of 25 human candidate genes that discriminated LSCs
from HSCs (Saito et al., 2010). Although early studies reported
CD93 expression on normal HSCs (Danet et al., 2002), CD93-
deficient mice are viable and display no major developmental
abnormalities (Norsworthy et al., 2004), suggesting that CD93 is
non-essential for HSC function, consistent with our observations
that human cord blood stem/progenitor cells do not express and
are not dependent on CD93, in contrast to MLLr LSCs.
Xenotransplantation assays showed that G1 phase CD34+
CD38CD93+ cells retained strong LSC function in serial trans-
plant assays, whereas G0 phase CD34+CD38CD93+ cells
from MLLr AML inefficiently engrafted primary recipients. Since
G0 reconstituted mice showed similar CD34/CD38 profiles and
cell-cycle status to those of G1 reconstituted mice (Figure S5B),1, October 1, 2015 ª2015 Elsevier Inc. 417
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Figure 7. CD93 Regulates the Cell Cycle
through Suppression of Cdkn2b in MLL
Leukemia
(A and B) Representative flow cytometry profiles
are shown for Hoechst/Pyronin Y staining ofmurine
MLL-AF9 AML (A) and human MLLr AML (B) cells
expressing control or CD93 shRNAs 6 days
following transduction.
(C) Bar graph shows cell-cycle stages of murine
MLL-AF9 leukemia cells with (shCD93) or without
(shLuc) CD93 knockdown after 6 days culture.
Data are mean values from three independent
experiments with statistically significant differ-
ences in G0 (p = 0.0231) and G1 (p = 0.0294)
subpopulations.
(D) Bar graph shows relative levels of CDKN2B
transcript determined by qRT-PCR of human MLLr
AML cells expressing shLuc or shCD93. Results
are the means of three leukemias and are ex-
pressed relative to shLuc control. *p = 0.0141.
(E) Bar graph shows relative levels of the indicated
transcripts determined by qRT-PCR of murine
MLL-AF9 leukemia cells expressing shLuc or
shCD93. Results are the means of four leukemias
in each category and are expressed relative to
shLuc control. *p = 0.041.
(F) BM progenitor/stem cells harvested from
wild-type or Cdkn2b/ mice were transduced
with the MLL-AF9 oncogene. Immortalized cells
from the third to fifth round of replating were
then transduced a second time with either
shCD93 or shLuc-expressing lentivirus. FACS-
sorted mCherry+/GFP+ cells were plated in
methylcellulose for 5 days to determine CFC
frequencies.
(G) Bar graph showing the relative CFC activity of
murine MLL-AF9 immortalized cells derived from
Cdkn2b+/+ or Cdkn2b/ BM cells compared with
(shCD93) or without (shLuc) CD93 knockdown.
Error bars indicate SDs of five independent ex-
periments. *p < 0.001.
(H) Representative images are shown for typical
colonies and morphologies (May Grunwald Gi-
emsa stain) of murine MLL-AF9 immortalized
cells derived from Cdkn2b+/+ or Cdkn2b/ BM
cells with (shCD93) or without (shLuc) CD93
knockdown after methylcellulose culture (day 5).
(I) Bar graph shows cell-cycle stages of Cdkn2b/
MLL-AF9-immortalized cells with (shCD93) or
without (shLuc) CD93 knockdown after 6 days in
culture. Data are representative of three indepen-
dent experiments.
(J) Survival curves are shown for Cdkn2b/ mice transplanted with murine MLL-AF9 AML cells (5,000 cells) transduced with shRNAs targeting CD93
or luciferase.
(K) Survival curves are shown for mice transplanted with murine MLL-AF9 AML cells transduced with Cdkn2b (n = 5) or control vector (n = 5).
See also Figure S7.the G0 fraction was likely contaminated with G1 AML cells
despite the extensive FACS procedure employed to prospec-
tively isolate rare CD34/CD38/CD93 subpopulations based on
their cell-cycle status. This is consistent with the long latency
and reduced penetrance for AMLs induced by the enriched G0
subpopulation (Table S4).
CD93 is a C-type lectin transmembrane receptor that has been
implicated in the modulation of phagocytosis, inflammation,
and cell adhesion (Nepomuceno et al., 1997; Norsworthy418 Cell Stem Cell 17, 412–421, October 1, 2015 ª2015 Elsevier Inc.et al., 2004; McGreal et al., 2002). It is expressed on cells
involved in inflammation, including myeloid cells, endothelial
cells, and platelets (Fonseca et al., 2001; Petrenko et al.,
1999; Nepomuceno and Tenner, 1998). However, its molecular
function has remained elusive. Although CD93 was originally
identified as a receptor for complement molecule C1q
(C1qRp), subsequent studies reported that CD93 alone did
not bind to C1q (Nepomuceno et al., 1997; McGreal et al.,
2002). The CD93 requirement for AML cell maintenance in
our culture assays suggests that its unknown ligand is present
in vitro. One possibility is that AML cells may produce the
ligand to sustain an autocrine loop, or alternatively CD93
may mediate essential homotypic cellular interactions to stim-
ulate LSC self-renewal divisions. Future studies are warranted
to address these possibilities.
Our studies link CD93 with cell-cycle regulation, and this
occurs in part through suppression of the cell-cycle inhibitor
p15Ink4b. Loss of CDKN2B (p15Ink4b) expression through muta-
tion or epigenetic silencing plays a prominent role in leukemia
pathogenesis. Hyper-methylation of the CDKN2B promoter oc-
curs frequently in AML (Drexler, 1998; Krug et al., 2002; Herman
et al., 1996; Chim et al., 2001) and is correlated with poor prog-
nosis (Wong et al., 2000; Shimamoto et al., 2005; Aggerholm
et al., 2006; Teofili et al., 2003). Furthermore, Cdkn2b-deficient
mice display increased susceptibility to retrovirus-induced AML
and develop non-reactive monocytosis and hematologic fea-
tures resembling chronic myelomonocytic leukemia (Wolff
et al., 2003; Bies et al., 2010). Thus, CDKN2B is a tumor suppres-
sor for myeloid leukemia; however, little is known about the
signals driving its repression in leukemogenesis. Our studies indi-
cate that lectin CD93, through currently undefined signaling
pathways, provides a novel upstream mechanism to suppress
CDKN2B expression and regulate LSC oncogenic potential in
MLLr AML. CDKN2B is one of several downstream mediators
of transforming growth factor b (TGF-b) signaling, which main-
tains a pool of quiescent HSCs (Dao et al., 2002), but the specific
role of CDKN2B is not clear and MLLr LSCs are not malignant
counterparts of HSCs, but rather,more downstreamprogenitors.
Previous studies have shown that CDKN2B levels are undetect-
able in CD34+ cells and upregulated during normal and leukemic
myeloid differentiation (Teofili et al., 2000). This suggests that
suppression of LSC cell division in MLLr leukemia cells by cell-
cycle inhibitors triggers the default outcome in the myeloid line-
age, which is differentiation. This may account for why there
appear to be few if any quiescent LSCs in MLLr leukemia.
Recently it was reported that cell-cycle regulator CDK6, but not
its functional homolog CDK4, is a crucial effector in MLLr AML
(Placke et al., 2014). Since CDKN2B forms a complex with
CDK6 to prevent its activation, our studies support a cell-cycle
regulatory pathway inwhichCD93 suppressesCDKN2B, thereby
freeing its target kinase CDK6 to drive cell-cycle progression and
unrestrained LSC self-renewal.
In summary, we identified lectin CD93 as an LSC-specific cell-
surface molecule in the genetic subtype of AML defined byMLL
rearrangements. LSCs marked by CD93 are actively cycling in
contrast to previous studies of quiescent cancer stem cells.
LSCs functionally require CD93, which regulates their differenti-
ation, self-renewal activity, and in vivo progression by modu-
lating the cell cycle through CDKN2B. These results suggest
that CD93 may be a useful candidate therapeutic target for
anti-LSC therapy and prognostic marker for quantitation of
minimal residual disease (MRD) for MLL-rearranged AML.EXPERIMENTAL PROCEDURES
Human Samples
Human AML samples (Table S1) and cord blood cells were obtained from
patients at the Stanford Medical Center with informed consent and institu-Cetional review board approval. Mononuclear cells were purified by Ficoll-density
gradient centrifugation enrichment.
Mice
Inbred C57BL/6 mice were used for syngeneic transduction/transplantation
experiments. NSG mice (NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ) were obtained
from the Jackson Laboratory and bred in a pathogen-free environment.
Cdkn2b/mice were maintained on a C57BL/6 background. All experiments
on mice in this study were performed with the approval of and in accordance
with Stanford University’s Administrative Panel on Laboratory Animal Care.
Cell Culture
Immortalized mouse myeloid cells or leukemia cells were cultured in
RPMI 1640 medium supplemented with 20% fetal calf serum (FCS) and
20% WEHI conditioned medium or cytokines (10 ng/ml IL-6, 20 ng/ml SCF).
293T and Phoenix cells were cultured in DMEM supplemented with 10% FCS.
In Vitro Colony Forming Assays
Mouse cells were plated in methylcellulose medium (M3231, Stem Cell Tech-
nologies) with cytokines as described previously (Lavau et al., 1997) and
counted after 5 days. Human cells were plated in H4535 (Stem Cell Technol-
ogies) and counted after 11–14 days of culture.
Flow Cytometry
Antibodies for flow cytometry were as follows. Anti-mouse antibodies used
were CD93-PE-Cy7 or Biotin (AA4.1), Mac1/CD11b-PE or FITC (M1/70),
Gr1-PE (RB6-8C5), B220-PE (RA3-6B2), F4/80-PE (BM8), NK1.1-PE
(PK136), TER119-PE (TER-119), IL-7Ra-PE (SB14), CD3-PE (145-2C12),
CD4-PE (GK1.5), CD8-PE (53-6.7), CD117-APC (2B8), Sca1-PE-Cy5 (D7),
CD16/32-PE-Cy7 (2.4G3), and CD34-FITC (RAM34) (all from eBioscience).
The lineage cocktail included the following mAbs: Mac1, Gr-1, B220,
TER119, IL-7Ra, NK1.1, CD3, CD4, and CD8. Anti-human antibodies were
CD34-APC (8G12) (BD Biosciences), CD38-PE-Cy7 (HIT2) (eBioscience),
CD93-PE or Biotin (R3) (eBioscience), CD45-APC or FITC (2D1 or H130)
(eBioscience and BD Bioscience), CD3-PE-Cy5 (UCHT1) (BD Biosciences)
and CD64-PE (10.1) (BioLegend). Analyses and cell sorting experiments
were performed using a FACS Vantage or FACSAria II (BDBiosciences) equip-
ped with Diva software (BD), and data were analyzed using FlowJo (Tree Star).
DNA Constructs and Virus Production
Retroviral constructs encoding HoxA9, Meis1, MLL-AF9, MLL-AF10, NUP98-
HOXA9, and E2A-HLF were reported previously (Wong et al., 2007; Somer-
vaille and Cleary, 2006; Iwasaki et al., 2005; Ayton and Cleary, 2003). The
pSicoR lentiviral vector (Ventura et al., 2004) with either mCherry or GFP
marker was used for knockdown studies. shRNAs were designed using
pSicoOligomaker v1.5 (developed by A. Ventura, Jacks Laboratory) and se-
quences are listed in the Supplemental Experimental Procedures. Retrovirus
and lentivirus production was performed as described previously (Wong
et al., 2007; Somervaille et al., 2009).
In Vivo Leukemogenesis Assays
FACS-sorted mouse AML cells were transplanted intravenously into suble-
thally irradiated (4.5Gy) C57BL/6 mice. Development of acute leukemia was
confirmed by blood smear, peripheral blood leukocyte counts, FACS analysis,
histology, or some combination thereof. For xenotransplant experiments,
FACS-sorted human AML cells were transplanted into sublethally irradiated
(2.5Gy) NSGmice, whichweremonitored for development of AML. In some ex-
periments, BMwas analyzed for engraftment (hCD45+) at 2–4 months. See the
Supplemental Experimental Procedures for more details of xenotransplant
experiments.
Microarray and Bioinformatics Analysis
Total RNA was extracted from prospectively isolated cells using Trizol reagent
(Invitrogen) followed by RNeasy MinElute Cleanup Kit (QIAGEN). Microarray
experiments were performed in the Stanford PAN Facility with mouse Genome
430 2.0 arrays (Affymetrix) and human Gene 1.0 ST arrays (Affymetrix). Micro-
array data were normalized with Expression Console software (Affymetrix) us-
ing RMA algorithms, then further normalized with dChip (Li and Wong, 2001).ll Stem Cell 17, 412–421, October 1, 2015 ª2015 Elsevier Inc. 419
GSEAs were performed using GSEA software (http://www.broad.mit.edu/
gsea) with a t test metric for gene ranking and 1,000 data permutations. GO
analysis was performed using MGI Gene Ontology Term Finder (http://proto.
informatics.jax.org/prototypes/GOTools/web-docs/MGI_Term_Finder.html).
Cell-Cycle Analysis
Cells were incubated with cell surface markers to enable our detection of
phenotypic subpopulations and then incubated with Hoechst 33342 (Sigma-
Aldrich) and Pyronin Y (Sigma-Aldrich) as previously described (Passegue´
et al., 2005).
qRT-PCR
RNA from sorted cell populations was purified using Trizol (Life Technologies).
cDNA was synthesized by SuperScript III First-Strand Synthesis System for
RT-PCR (Life Technologies) according to the manufacturer’s instructions.
Real-time PCR was performed with TaqMan probes (Life Technologies) using
b-Actin or b-ACTIN as internal control. TaqMan probes for the following
mouse and human genes were purchased from Life Technologies:
Cd93 (Mm00440239_g1), Meis1 (Mm00487664_m1), Cdkn1a (p21)
(Mm01303209_m1), Cdkn1b (p27) (Mm00438167_g1), Cdkn2a (p19Arf)
(Mm01257348_m1), Cdkn2b (p15Ink4b) (Mm00483241_m1), Cdkn2c (p18Ink4c)
(Mm00483243_m1), b-Actin (Mm00607939_s1); CD93 (Hs00362607_m1),
and b-ACTIN (HS01060665_g1). Primers for mouse p16Ink4a were reported
previously (Zhang et al., 2003) and purchased from Life Technologies.
Statistical Analysis
Statistics were calculated using Prism 6 software (GraphPad software, Inc).
Data were presented as themean ± SD. The significance of the differences be-
tween groups was determined via Student’s t test.
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